An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function
Latest Information Update: 09 May 2019
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure; Hypertension
- Focus Pharmacokinetics
- Sponsors Novartis
- 26 May 2016 Results of impact of renal impairment on pharmacokinetics of LCZ-696 published in the European Journal of Clinical Pharmacology
- 13 Apr 2012 New trial record